Product Name: CD1a Antibody [C1A/711]
Species Reactivity: Human
Tested Applications: Flow, IF, IHC
Applications: Flow Cytometry: 0.5-1 ug/million cellsIF: 1-2 ug/mlIHC (FFPE): 0.5-1 ug/ml for 30 min at RT (1)Prediluted format : incubate for 30 min at RT (2)The concentration stated for each application is a general starting point. Variations in protocols, secondaries and substrates may require the antibody to be titered up or down for optimal performance.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate Buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
User Note: Optimal dilutions for each application to be determined by the researcher
Predicted Molecular Weight:
Immunogen: Recombinant human CD1a protein was used as the immunogen for this antibody.
Host Species: Mouse
Purification: Protein G affinity chromatography
Physical State: Liquid
CAS NO.: 1599432-08-2
Product: NIBR189
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Conditions: Aliquot and Store at -20C. Avoid freez-thaw cycles.
Clonality: Monoclonal
Conjugate: Unconjugated
Alternate Names: T-cell surface glycoprotein CD1a, T-cell surface antigen T6/Leu-6, hTa1 thymocyte antigen, CD1a, CD1A
Accession NO.:
Protein Ino:
Official Symbol: CD1A
Geneid: 909
Background: At least five CD1 genes (CD1a, b, c, d, and e) are identified. CD1 proteins have been demonstrated to restrict T cell response to non-peptide lipid and glycolipid antigens and play a role in non-classical antigen presentation. CD1a is a non-polymorphic MHC Class 1 related cell surface glycoprotein, expressed in association with Beta-2 microglobulin. CD1a antibody labels Langerhans cell histiocytosis (Histiocytosis X), extranodal histiocytic sarcoma, a subset of T-lymphoblastic lymphoma/leukemia, and interdigitating dendritic cell sarcoma of the lymph node. When combined with antibody against TTF-1 and CD5, CD1a antibody is useful in distinguishing between pulmonary and thymic neoplasms since CD1a is consistently expressed in thymic lymphocytes in both typical and atypical thymomas, but only focally in 1/6 of thymic carcinomas and not in lymphocytes in pulmonary neoplasms. antibody to CD1a is reported to be a new marker for perivascular epithelial cell tumor (PEComa).
PubMed ID:http://aac.asm.org/content/34/3/409.abstract
